IM Therapeutics

IM Therapeutics

  • Founded: 2015
  • Location: Woburn, MA
  • Employee range: 1 - 10
  • Clinical stage: Clin1b
  • Therapy area: Diabetes (1)
  • Drug types: END, GI, IMM
  • Lead product: IMT-002
  • Product link:
  • Funding: $10M A Oct 2019

Short description:

Personalized immuno-therapeutic drugs for autoimmune diseases

Drug notes:

Undisclosed RD Celiac disease, undisclosed programs RD autoimmune diseases

Long description:

IM Therapeutics is developing immunotherapeutic drugs for autoimmune diseases. Autoimmune diseases affect about 4% of the world’s population manifested through 80 different disease conditions. Gene variants of HLA protein are common mutations associated with the disease. Using their technology platform, IMT is screening millions of drug-like molecules using computational algorithms and 3D models to see if they can target specific HLA proteins, preventing an autoimmune response. Currently, IMT is prioritizing therapies for Type 1 Diabetes and Celiac Disease.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy